Clinical Trials Using Ipilimumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Ipilimumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 151-167 of 167
< Previous 1 ... 5 6 7

  • Lenalidomide and Ipilimumab after Stem Cell Transplant in Treating Patients with Hematologic or Lymphoid Malignancies

    This pilot clinical trial studies the side effects of lenalidomide and ipilimumab after stem cell transplant in treating patients with hematologic or lymphoid malignancies. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide with ipilimumab may be a better treatment for hematologic or lymphoid malignancies.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ipilimumab and Imatinib Mesylate in Treating Patients with Metastatic or Unresectable Solid Tumors

    This phase I trial studies the side effects and best dose of ipilimumab and imatinib mesylate in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ipilimumab and imatinib mesylate may work better in treating patients with solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types

    A study evaluating the drug levels of ipilimumab alone and in combination with nivolumab applied under the skin in various tumor types
    Location: UCSF Medical Center-Mission Bay, San Francisco, California

  • A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

    The purpose of the study is to assess the effectiveness of re-induction with Nivolumab combined with ipilimumab.
    Location: 2 locations

  • Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

    An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV) negative squamous cell carcinoma of head and neck that have failed to respond to standard therapy, progressed despite standard therapy, for which standard therapy does not offer the potential for increased survival.
    Location: See Clinical Trials.gov

  • An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

    The purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and / or overall survival compared with chemotherapy in patients with advanced lung cancer.
    Location: University of California San Diego, San Diego, California

  • Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients with Relapsed / Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

    This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well they work in treating patients with cancers that have come back (relapsed) or does not respond to treatment (refractory) and have an increased number of genetic changes. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tumor mutational burden (TMB) is the total amount of genetic changes or "mutations" found in tumor cells. Some studies in adults with cancer have shown that patients with a higher TMB (an increased number of genetic changes) are more likely to respond to immunotherapy drugs. There is also evidence that nivolumab and ipilimumab can shrink or stabilize cancer in adult patients with cancer. This study is being done to help doctors learn if the combination of nivolumab and ipilimumab can help children, adolescents, and young adults patients live longer.
    Location: See Clinical Trials.gov

  • Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

    The purpose of this study is to evaluate the role of neoadjuvant immunotherapy and to demonstrate high pathologic complete response (pCR) and near pCR rates in melanoma participants with clinically detectable nodal disease and a high risk of recurrence. Neoadjuvant immunotherapy aims to enhance the systemic T-cell response to tumor antigens while detectable tumor is still present, inducing a stronger and broader tumor-specific immune response. Of the neoadjuvant approaches studied within melanoma, the neoadjuvant combination of nivolumab and ipilimumab has demonstrated high pCR and near pCR rates that may translate to prolonged clinical benefit.
    Location: 2 locations

  • Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

    This phase II trial studies how well polarized dendritic cell (aDC1) vaccine, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 vaccine contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body’s natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if aDC1 vaccine, interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and / or progression of melanoma.
    Location: Roswell Park Cancer Institute, Buffalo, New York

  • Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients with Merkel Cell Cancer

    This phase I trial studies the side effects and how well nivolumab works when given together with radiation therapy or ipilimumab as adjuvant therapy in treating patients with Merkel cell cancer. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons or other sources to kill tumor cells and shrink tumors. Giving nivolumab with radiation therapy or ipilimumab after surgery may kill any remaining tumor cells.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Nivolumab, Ipilimumab, and Plinabulin in Treating Patients with Recurrent Extensive Stage Small Cell Lung Cancer

    This phase I / II trial studies the side effects and best dose of plinabulin when given together with nivolumab and ipilimumab and to see how well they work in treating patients with extensive stage small cell lung cancer that has come back. Plinabulin blocks tumor growth by targeting both new and existing blood vessels going to the tumor as well as killing tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving plinabulin with nivolumab and ipilimumab may work better in treating patients with extensive stage small cell lung cancer compared to standard chemotherapy.
    Location: 5 locations

  • Ipilimumab and Nivolumab as First-Line Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This phase II trial studies how well ipilimumab and nivolumab work as first-line therapy in treating patients with stage IV non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 7 locations

  • Nivolumab with and without Ipilimumab and Radiation Therapy in Treating Patients with Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma before Surgery

    This phase II trial studies how well nivolumab with and without ipilimumab and radiation therapy when given before surgery works in treating patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma that can be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab, ipilimumab, and radiation therapy may work better in treating patients with undifferentiated pleomorphic sarcoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ipilimumab and Nivolumab in Treating Patients with Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer

    This phase II trial studies how well ipilimumab and nivolumab work in treating patients with non-small cell lung cancer that is stage IIIB, stage IV, or that has come back. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Yale University, New Haven, Connecticut

  • Nivolumab and Ipilimumab in Treating Patients with Metastatic or Refractory Thyroid Cancer

    This randomized phase II trials studies how well nivolumab and ipilimumab work treating patients with thyroid cancer that has spread to other places in the body (metastatic) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: Dana-Farber Cancer Institute, Boston, Massachusetts

  • Ipilimumab and TLR9 Agonist MGN1703 in Treating Patients with Advanced or Metastatic Solid Tumors

    This phase I trial studies the side effects, best dose, and best way to give TLR9 agonist MGN1703 when given together with ipilimumab in treating patients with solid tumors that are no longer responding to treatment or have spread to other places in the body (advanced / metastatic). Biological therapies, such as TLR9 agonist MGN1703, use substances made from living organisms that may stimulate the immune system to kill tumor cells. Monoclonal antibodies, such as ipilimumab, may interfere with the ability of tumor cells to grow and spread. Giving TLR9 agonist MGN1703 and ipilimumab may work better in treating patients with advanced solid tumors.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma

    This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
    Location: OHSU Knight Cancer Institute, Portland, Oregon


< Previous 1 ... 5 6 7